These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6316195)

  • 1. Characterization of a kappa-agonist-like antinociceptive action of tifluadom.
    Upton N; Gonzalez JP; Sewell RD
    Neuropharmacology; 1983 Oct; 22(10):1241-2. PubMed ID: 6316195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interaction of the two isomers of the opioid benzodiazepine tifluadom with mu-, delta-, and kappa-binding sites and their analgesic and intestinal effects in rats.
    Petrillo P; Amato M; Tavani A
    Neuropeptides; 1985 Feb; 5(4-6):403-6. PubMed ID: 2860598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spinal antinociceptive actions and naloxone reversibility of intravenous mu- and kappa-opioids in spinalized rats: potency mismatch with values reported for spinal administration.
    Parsons CG; West DC; Headley PM
    Br J Pharmacol; 1989 Oct; 98(2):533-43. PubMed ID: 2555012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of intravenous mu and kappa opioid receptor agonists on sensory responses of convergent neurones in the dorsal horn of spinalized rats.
    Dong XW; Parsons CG; Headley PM
    Br J Pharmacol; 1991 May; 103(1):1230-6. PubMed ID: 1652344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antinociceptive profiles of mu and kappa opioid agonists in a rat tooth pulp stimulation procedure.
    Steinfels GF; Cook L
    J Pharmacol Exp Ther; 1986 Jan; 236(1):111-7. PubMed ID: 2867210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between mu and kappa opioid agonists in the rat drug discrimination procedure.
    Negus SS; Picker MJ; Dykstra LA
    Psychopharmacology (Berl); 1990; 102(4):465-73. PubMed ID: 1965748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kappa-opioid receptor-mediated antinociception in the rat. I. Comparative actions of mu- and kappa-opioids against noxious thermal, pressure and electrical stimuli.
    Millan MJ
    J Pharmacol Exp Ther; 1989 Oct; 251(1):334-41. PubMed ID: 2571722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of potent mu and kappa-opiate agonists using heat and pressure antinociceptive profiles and combined potency analysis.
    Upton N; Sewell RD; Spencer PS
    Eur J Pharmacol; 1982 Mar; 78(4):421-9. PubMed ID: 6122588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kappa-opioid diuretic effects of tifluadom, a benzodiazepine opioid agonist.
    Leander JD
    J Pharm Pharmacol; 1984 Aug; 36(8):555-6. PubMed ID: 6148404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agonist and antagonist activity of kappa opioids in the squirrel monkey: I. Antinociception and urine output.
    Craft RM; Dykstra LA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):327-33. PubMed ID: 1309876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar actions of kappa and mu agonists on spinal nociceptive reflexes in rats and their reversibility by naloxone.
    Parsons CG; West DC; Headley PM
    NIDA Res Monogr; 1986; 75():461-4. PubMed ID: 2828992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mu antagonist properties of kappa agonists in a model of rat urinary bladder motility in vivo.
    Sheldon RJ; Nunan L; Porreca F
    J Pharmacol Exp Ther; 1987 Oct; 243(1):234-40. PubMed ID: 2822899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tifluadom, a kappa-opiate agonist, acts as a peripheral cholecystokinin receptor antagonist.
    Chang RS; Lotti VJ; Chen TB; Keegan ME
    Neurosci Lett; 1986 Dec; 72(2):211-4. PubMed ID: 3027627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of mu and kappa opioid receptor agonists on rat plasma corticosterone levels.
    Hayes AG; Stewart BR
    Eur J Pharmacol; 1985 Oct; 116(1-2):75-9. PubMed ID: 2996912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of [3H][3-MeHis2]thyrotropin releasing hormone recognition sites in the rat brain by tifluadom, a kappa opiate receptor agonist.
    Das S; Bhargava HN
    Neuropharmacology; 1987 Aug; 26(8):1141-6. PubMed ID: 2889163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
    Ward SJ; Takemori AE
    J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists.
    Picker MJ; Dykstra LA
    J Pharmacol Exp Ther; 1989 May; 249(2):557-66. PubMed ID: 2566680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of mechanical withdrawal responses and effects of mu-, delta- and kappa-opioid agonists in normal and mu-opioid receptor knockout mice.
    Fuchs PN; Roza C; Sora I; Uhl G; Raja SN
    Brain Res; 1999 Mar; 821(2):480-6. PubMed ID: 10064835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of tifluadom on cholecystokinin-induced antinociception.
    Gericke M; Morgenstern R; Ott T
    Eur J Pharmacol; 1990 May; 180(1):187-90. PubMed ID: 2365002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agonist and antagonist activity of kappa opioids in the squirrel monkey: II. Effect of chronic morphine treatment.
    Craft RM; Dykstra LA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):334-42. PubMed ID: 1309877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.